Versant Venture Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Versant Venture Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-101,855	Closed	-$121K	–	8
2022 Q3	$121K	Hold	101,855	–	–	0.21%	8
2022 Q2	$183K	Hold	101,855	–	–	0.28%	8
2022 Q1	$206K	Hold	101,855	–	–	0.21%	10
2021 Q4	$276K	Hold	101,855	–	–	0.15%	10
2021 Q3	$454K	Hold	101,855	–	–	0.19%	11
2021 Q2	$591K	Hold	101,855	–	–	0.2%	11
2021 Q1	$715K	Hold	101,855	–	–	0.14%	11
2020 Q4	$489K	Hold	101,855	–	–	0.05%	12
2020 Q3	$594K	Hold	101,855	–	–	0.11%	10
2020 Q2	$688K	Hold	101,855	–	–	0.1%	11
2020 Q1	$648K	Hold	101,855	–	–	0.18%	8
2019 Q4	$1.06M	Hold	101,855	–	–	0.32%	7
2019 Q3	$400K	Hold	101,855	–	–	0.15%	8
2019 Q2	$1.51M	Hold	101,855	–	–	0.44%	8
2019 Q1	$2.53M	Hold	101,855	–	–	0.83%	7
2018 Q4	$1.83M	Hold	101,855	–	–	0.91%	8
2018 Q3	$2.99M	Hold	101,855	–	–	1.02%	9
2018 Q2	$4.63M	Hold	101,855	–	–	1.44%	8
2018 Q1	$5.38M	Hold	101,855	–	–	1.72%	8
2017 Q4	$6.93M	Hold	101,855	–	–	7.29%	7
2017 Q3	$8.38M	Hold	101,855	–	–	6.38%	5
2017 Q2	$9.54M	Sell	101,855 -305,561	-75%	-$18.7M	7.51%	5
2017 Q1	$25.9M	Hold	407,416	–	–	18.86%	3
2016 Q4	$18.1M	Hold	407,416	–	–	17.61%	3
2016 Q3	$14.7M	Hold	407,416	–	–	16.38%	4
2016 Q2	$5.59M	Hold	407,416	–	–	5.66%	3
2016 Q1	$7.82M	Hold	407,416	–	–	5.65%	4
2015 Q4	$14.3M	Hold	407,416	–	–	8.34%	4
2015 Q3	$37.5M	Hold	407,416	–	–	21.49%	2
2015 Q2	$35.8M	Sell	407,416 -407,417	-50%	-$34.9M	45.41%	1
2015 Q1	$60.5M	Hold	814,833	–	–	53.2%	1
2014 Q4	$45.6M	Buy	+814,833	New	+$42.8M	43.63%	1

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Versant Venture Management's CLVS Position: Q4 2022 in Review

Versant Venture Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 101,855 shares — an estimated $121K sold.

Versant Venture Management first reported a position in CLVS in Q4 2014 and held it in 32 quarters. The position peaked at $60.5M in Q1 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Versant Venture Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Versant Venture Management sold 101,855 Clovis Oncology, Inc. shares in Q4 2022, an estimated $121K.
Versant Venture Management first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 32 quarters.
Versant Venture Management's Clovis Oncology, Inc. position peaked at $60.5M in Q1 2015.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Versant Venture Management's 13F filing for Q4 2022, filed 9 Feb 2023.